Equities

StemCell Institute Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
7096:TYO

StemCell Institute Inc

Actions
Health CareHealth Care Providers
  • Price (JPY)844.00
  • Today's Change-11.00 / -1.29%
  • Shares traded11.60k
  • 1 Year change-44.11%
  • Beta1.5366
Data delayed at least 15 minutes, as of Feb 06 2026 06:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

StemCell Institute Inc is mainly engaged in the cell bank business, which separates and stores cord blood. The Company operates cell bank business from umbilical cord blood and umbilical cord, development of new treatment methods and regenerative medicine products, regenerative medicine and fertility treatment, business development and investment in childbirth and childcare areas. The Company operates Cell Bank business segment. After signing the contract for the separation and storage of umbilical cord blood with customers (pregnant women), the umbilical cord blood collected at domestic umbilical cord blood collection cooperative hospitals (university hospitals, obstetric clinics and others) is collected, and carried into its cell processing center in Minato-ku, Tokyo and Midori-ku, Yokohama. It is stored at its cell storage center (Midori-ku, Yokohama, Kanagawa) for a long time at ultra-low temperature after stem cells contained in cord blood being separated, extracted and prepared.

  • Revenue in JPY (TTM)2.72bn
  • Net income in JPY198.73m
  • Incorporated1999
  • Employees117.00
  • Location
    StemCell Institute IncMatsuoka Tamuracho Bldg.5-22-10, ShimbashiMINATO-KU 105-0001JapanJPN
  • Phone+81 368113230
  • Fax+81 368113240
  • Websitehttps://stemcell.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Living Platform Ltd20.71bn442.01m5.38bn1.21k12.242.396.160.260198.1998.194,614.50502.011.74350.0612.5417,084,610.003.712.144.983.0010.779.912.131.581.204.270.73640.0015.2519.9693.0828.41-16.48--
Shigematsu Works Co Ltd14.25bn568.94m5.86bn390.0010.170.66574.210.411380.0080.002,003.791,222.830.79452.044.0936,537,640.003.174.494.757.1430.6531.443.995.190.835517.800.414513.798.604.0033.6424.0329.828.45
Care Twentyone Corp48.16bn384.17m6.49bn6.32k15.371.333.550.134728.4328.433,566.14327.361.54783.717.647,621,168.001.431.352.351.9523.0922.820.92951.111.0520.400.80550.046.087.2237.98-11.42-15.957.82
As Partners Co Ltd20.94bn1.14bn8.55bn879.007.531.696.590.4084316.94316.945,800.971,416.391.075.839.5523,822,800.005.83--11.48--19.38--5.47--0.919418.210.596--4.47--69.75------
Uchiyama Holdings Co Ltd29.44bn2.13bn8.63bn2.27k3.620.5303.280.293110.11110.111,518.29752.780.966957.4310.8512,979,990.007.01-0.66969.43-0.92337.024.727.25-0.7612.2112.460.4452--0.9117-0.7977858.92278.17-8.230.00
StemCell Institute Inc2.72bn198.73m8.76bn117.0043.853.3026.013.2219.5019.50266.94259.060.367920.681.4323,251,740.002.694.036.519.9961.8363.587.3110.451.21--0.135923.487.989.8324.066.8154.63--
Japan Hospice Holdings Inc13.60bn506.31m8.80bn1.09k17.342.378.100.646960.2160.211,614.46439.580.7687--6.6212,433,290.002.864.013.424.7714.6518.613.725.26--2.290.76875.8422.7323.64-6.2016.51109.92--
Advantage Risk Management Co., Ltd.9.75bn1.06bn10.06bn519.009.282.374.951.0366.6266.62615.70260.891.10--8.0618,792,050.0011.917.4718.8911.5467.3372.1910.837.00--314.470.312241.6922.2310.2047.233.0925.717.78
Sunwels Co Ltd26.82bn-2.68bn11.97bn3.30k--1.55--0.4466-82.76-82.76826.87219.070.62841,764.005.868,121,139.00-6.292.79-7.413.5911.1924.62-10.013.171.27-1.140.803538.5924.0443.33-145.52--51.83--
Wellness Communications Corp14.52bn832.91m12.23bn122.0014.322.2611.150.842268.4968.491,213.83434.041.8334.975.39118,992,300.0010.51--19.49--20.05--5.74--2.04--0.00--5.96--14.08------
Data as of Feb 06 2026. Currency figures normalised to StemCell Institute Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

3.31%Per cent of shares held by top holders
HolderShares% Held
Ichiyoshi Asset Management Co., Ltd.as of 30 Jun 2025268.20k2.62%
Rheos Capital Works, Inc. (Investment Management)as of 18 Nov 202465.40k0.64%
Simplex Asset Management Co., Ltd.as of 08 Jan 20266.00k0.06%
Amundi Japan Ltd.as of 10 Sep 20250.000.00%
Deutsche Asset Management (Japan) Ltd.as of 11 Mar 20240.000.00%
Amova Asset Management Co., Ltd.as of 17 Jul 20250.000.00%
Meiji Yasuda Asset Management Co. Ltd.as of 12 Aug 20250.000.00%
SBI Asset Management Co., Ltd.as of 23 Jun 20250.000.00%
More ▼
Data from 23 Jun 2025 - 28 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.